Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

By N. Sattar, D. Preiss, Heather Murray, P. Welsh, B. Buckley, Anton J.M. de Craen, S. Seshasai, John J McMurray, Dilys J. Freeman, J. Jukema and 23 more. The Lancet, 2010

2,174 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/1ad4fed703af6fbf4c849cdbd7621637a3e35a19

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Surgery

Citations in the corpus

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (2019, positive): “17) in the risk of being diagnosed with diabetes mellitus compared with placebo or standard care.(113) Weaknesses of this analysis include its use of study-level rather than individual participant data, the fact that newly diagnosed diabetes mellitus was not a prespecified outcome in the vast majori”
Standards of Medical Care in Diabetes—2013 (2012, background): “There is an increased risk of incident diabetes with statin use (289,290), which may be limited to those with risk factors for diabetes.”
Cardiovascular disease in women (2010, neutral): “17); however, no sex-specific analysis was performed.(141) Overall, the benefit of statins from reduction in coronary events seems to exceed the risk related to DM in both men and women.”
Interpretation of the evidence for the efficacy and safety of statin therapy. (2016, background): “In subsequent meta-analyses of the available results from the randomized trials, standard statin dose regimens were associated with a proportional increase of about 10% in reported diabetes, and more intensive statin regimens (as used in JUPITER) with about a 10% further increase.(48,225) This exces”
Standards of Medical Care in Diabetes—2014 (2013, background): “4 vascular events among those255patients (360).”
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “Recent studies have suggested an increased incidence of DM in patients treated with statins.(247) These observations have been seen in Mendelian randomization studies and in clinical trials, although the effect appears greatest in patients already at high risk for DM (e.”
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “year have been observed for high-intensity statins (52,82).”
The MR-Base platform supports systematic causal inference across the human phenome (2018, result): “The latter result is compatible with trials that have shown that lipid lowering drugs similarly increase risk of type two diabetes ( Swerdlow et al., 2015 ; Schmidt et al., 2017 ; Sattar et al., 2010 ).”
Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. (2014, background): “3 exces s cases of diabetes 100 statin-treated individuals per year have been observed for high-intensity statins (52,82).”
Mechanisms of diabetic complications. (2013, background): “This issue remains an ongoing controversy (473, 518), but it appears that effects of statin therapy on the development of diabetes, either positive or negative, are modest at best.”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “The number needed to cause one case of diabetes was estimated at 255 over 4 years.(225) However, the risk is higher with the more potent statins in high doses,(226) and the risk for diabetes is higher in the elderly and in the presence of other risk factors for diabetes such as overweight or insulin”